MEREO BIOPHARMA (MREO)
(Delayed Data from NSDQ)
$4.15 USD
0.00 (0.00%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $4.15 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth NA Momentum NA VGM
Price, Consensus and EPS Surprise
MREO 4.15 0.00(0.00%)
Will MREO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MREO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MREO
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
MREO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates
Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat
Other News for MREO
Mereo BioPharma price target raised by $2 at Leerink, here's why
Biotech Alert: Searches spiking for these stocks today
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
Mereo BioPharma’s Public Offering and Strategic Underwriter Partnership
Baird starts Mereo at outperform, sees alvelestat as underappreciated